Entry Detail



General Information

Database ID:exR0078820
RNA Name:PGK1
RNA Type:mRNA
Chromosome:chrX
Starnd:+
Coordinate:
Start Site(bp):77910739End Site(bp):78129295
External Links:ENSG00000102144



Disease Information

Disease Name:Fragile X Syndrome
Disease Category:Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:D005600
Type:Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA



Expression Detail

GEO ID:GSE83556
Description:Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:Disease vs Control
Case Disease Type:Fragile X Syndrome
Case Disease SubType:NA
Case Sample:Fragile X Syndrome
Control Sample:Normal
Number of Case:22
Number of Control:18
Number of Samples:40





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
AIFM2
chr10
70098223
70132934
-
AC012254.2
chr18
47108188
47176345
-
AKIRIN2
chr6
87674860
87702233
-
AHSA1
chr14
77457870
77469472
+
AC011005.1
chr7
129126518
129130793
+
ADPGK
chr15
72751369
72785846
-
AKIRIN1
chr1
38991276
39006059
+
ABCC5
chr3
183919934
184017939
-
ABCB7
chrX
75051048
75156732
-
AFF4
chr5
132875395
132963634
-
ADCY5
chr3
123282296
123449758
-
AL121753.1
chr20
35267885
35280043
-
AC010422.5
chr19
12664828
12669397
-
AGGF1
chr5
77029251
77065234
+
ACTG1
chr17
81509971
81523847
-
ADGRB2
chr1
31727117
31764893
-
ABCE1
chr4
145098288
145129524
+
ACTR3
chr2
113890063
113962596
+
AC023055.1
chr12
55757275
55827546
-
AL355987.1
chr9
136738167
136748453
-
ADH5
chr4
99070978
99088801
-
ACAT1
chr11
108116695
108147603
+
AC008581.2
chr5
77030902
77152155
+
AFTPH
chr2
64524305
64593005
+
AAMP
chr2
218264123
218270257
-
ALDOA
chr16
30064164
30070457
+
ACTB
chr7
5527148
5563784
-
AL133352.1
chr10
100505628
100529881
-
ALDH3A2
chr17
19648136
19685760
+
AGFG1
chr2
227472152
227561214
+
miRNA targets:
miRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa-miR-29b-3p
chr7
130877467
130877489
-
hsa-miR-30c-5p
chr6
71377003
71377025
-
hsa-miR-136-5p
chr14
100884716
100884738
+
hsa-miR-299-3p
chr14
101023832
101023853
+
circRNA targets:NA
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC000068.1
chr22
19447893
19450105
+
AC007952.4
chr17
19112000
19112636
-
AC020663.1
chr16
4730115
4752565
-
AC023509.1
chr12
53441741
53467528
+
AC048341.2
chr12
62603909
62604399
+
AC074183.1
chr7
84939349
84940245
-
AC079781.5
chr7
97851688
97972985
-
AC091132.5
chr17
45549781
45558738
-
AC106864.1
chr4
112693047
112706810
-
AC113189.4
chr17
7439506
7445966
+
AC132217.1
chr11
2129121
2129964
-
AC133644.3
chr2
87455476
87767359
+
AL022311.1
chr22
37876148
37895563
+
AL137026.2
chr10
44259602
44261813
-
Display:



Experiment Detail

GEO ID:GSE83556
Sample Source:Amniotic Fluid
Source Fraction:Supernatant
Platform:GPL570
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:17063
Sample treatment protocol:RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).



Reference

PMID:NA
Title:NA
Author:NA
Journal:NA
Description:NA